Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
PI3Kγ inhibitor
DRUG CLASS:
PI3Kγ inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
duvelisib (26)
IPI-549 (6)
RP6530 (6)
BR101801 (1)
CB-006-3 (1)
CZC24832 (1)
AZD3458 (0)
ZX-101A (0)
ZX-4081 (0)
duvelisib (26)
IPI-549 (6)
RP6530 (6)
BR101801 (1)
CB-006-3 (1)
CZC24832 (1)
AZD3458 (0)
ZX-101A (0)
ZX-4081 (0)
›
Associations
(41)
News
Trials
Search handles
@DrRaulCordoba
@majorajay
@neerajaiims
Search handles
@DrRaulCordoba
@majorajay
@neerajaiims
Filter by
Latest
10ms
Duvelisib led to a high response rate in patients w/ peripheral T-cell lymphoma, with activity favoring patients with PTCL not otherwise specified and angioimmunoblastic T-cell lymphoma. @NehaMehtaShahMD @WUSTLmed @icmlugano #17ICML #lymsm https://t.co/v5J1uSXhsl (@OncLive)
10 months ago
Clinical
|
Copiktra (duvelisib)
10ms
Duvelisib led to a high response rate in patients w/ peripheral T-cell lymphoma, with activity favoring patients with PTCL not otherwise specified and angioimmunoblastic T-cell lymphoma. @NehaMehtaShahMD @WUSTLmed @icmlugano #17ICML #lymsm https://t.co/TJCxD8CBUh (@OncLive)
10 months ago
Clinical
|
Copiktra (duvelisib)
10ms
Based on clinical activity and safety profile in phase I Hong et al now investigate phosphoinositide 3 kinase γ inhibitor eganelisib in a phase II trial in patients with advanced solid tumors as monotherapy and with #nivolumab. https://t.co/ze0FJuzR6J @DavidHongMD (@CCR_AACR)
10 months ago
Clinical • Metastases
|
PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma)
|
Opdivo (nivolumab) • eganelisib (IPI-549)
10ms
Duvelisib Demonstrates Higher Activity in Angioimmunoblastic Peripheral T-Cell Lymphoma @NehaMehtaShahMD @WUSTLmed @icmlugano #17ICML #lymsm https://t.co/vb4qA0I7UF (@OncLive)
10 months ago
Copiktra (duvelisib)
10ms
Phase 2 data of duvelisib in R/R PTCL with 50% ORR, but quite toxic with one-third cutaneous reactions and diarrhea (PROs would be helpful here) and 3 grade 5 AEs. Discontinuation d/t LFTs relatively common. #lymsm #17ICML (@majorajay)
10 months ago
P2 data
|
Copiktra (duvelisib)
over3years
An Emory University-led phase 2 study will evaluate whether the the PI3K-gamma/delta inhibitor duvelisib is effective at reducing lung inflammation in patients with severe #COVID-19. @EmoryUniversity @ekwaller #coronavirus #lcsm https://t.co/RlJI3IRJVu (@OncLive)
over 3 years ago
Clinical
|
PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma)
|
Copiktra (duvelisib)
4years
Exciting. Novel first in-class, oral immuno-oncology agent ( PI3K-gamma inhibitor). Nice to see something beyond PD-1/L1 inhibitor in advanced bladder cancer. @BladderCancerUS @montypal @PGrivasMDPhD @ASCO_pubs @ASCOPost @VivekSubbiah @MattGalsky (@neerajaiims)
4 years ago
PD-1 (Programmed cell death 1)
6years
Dual PI3K-δ,γ inhibitor duvelisib reduces immunosuppressive Tregs and myeloid cells enhancing efficacy of checkpoint and co-stimulatory antibodies in a B cell #lymphoma model @ASCO @sitcancer #ImmunoOnc #lymsm https://t.co/KtQ9IyOQuG (@DrRaulCordoba)
6 years ago
Clinical • Preclinical
|
Copiktra (duvelisib)
over6years
"Bayer boosted as #FDA OKs its PI3K drug Aliqopa for relapsed follicular #lymphoma patients https://t.co/UVzecHPqTd #biopharma #pharma" (@endpts)
over 6 years ago
Clinical
|
Aliqopa (copanlisib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login